NOVIXO AI PRIVATE LIMITED

In their own words

Novixo operates in the life sciences industry, specializing in pharmacovigilance. We are developing IntakeX, an AI-powered case intake tool designed to streamline the collection, classification, and processing of safety reports in the pharmaceutical sector. Innovation: IntakeX incorporates the industry’s first pharmacovigilance-specific Large Language Model (LLM), engineered to meet the complex regulatory and operational requirements of pharmacovigilance workflows. This allows for intelligent automation of case intake, classification, and prioritization, improving accuracy and efficiency while reducing manual effort. Impact: IntakeX enables organizations to handle high volumes of safety cases automatically, ensuring regulatory compliance and operational excellence. By automating critical processes, it enhances productivity, supports regulated product monitoring, and offers a scalable solution for the broader life sciences sector. Stage: We are currently developing the Minimum Viable Product (MVP), which is expected to be ready by January 26. The technology promises significant potential for scalability, employment generation, and value creation in pharmacovigilance operations.

Written by the company on its public Startup India profile. Not verified by us.